Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.

Ayelet GrupperNechama SharonTalya FinnRegev CohenMeital IsraelAmir AgbariaYoav RechaviIdit F SchwartzDoron SchwartzYonatan LellouchMoshe Shashar

Published in: Clinical journal of the American Society of Nephrology : CJASN (2021)

Although most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.

Keyphrases

end stage renal disease
immune response
chronic kidney disease
peritoneal dialysis
patients undergoing
ejection fraction
healthcare
newly diagnosed
prognostic factors